Best Integrative, Alternative, Complementary Cancer Center, Manila

These findings indicate that berberine and enzalutamide represent a promising combination for further investigation, particularly in prostate tumors that have acquired resistance to standard care. The authors also noted that the specific AMPK-mTORC1 mechanism highlighted in the study could serve as a valuable framework to guide the development of future drug combinations intended to bypass resistance mechanisms.

https://www.independent.co.uk/news/world/americas/ucla-maestro-ai-prostate-cancer-b3071625.html